McMaster University engineers have devised a way to make testing for new drugs more efficient and affordable, and reduce the time for helpful medications to reach the public
Chemical Engineering Associate Professor Todd Hoare and Rabia Mateen, a PhD candidate in Biomedical Engineering, have created a printed paper-based device that can speed up and improve the accuracy of the drug screening process. Their work, which could also be used to diagnose diseases, identify environmental contaminants and pinpoint biological warfare agents, was published in Nature Communications in February.
Currently, drug testing is done in multiple stages, with the first stage involving testing thousands of drug candidates in rapid succession to see how well they bind, block or degrade a molecule of interest to the target disease. Subsequent stages involve more extensive testing of drugs that show promise in this first step.
However, the way this initial first screen is now done results in many inaccurate results, with as many as 95% of drug candidates having no chance of becoming a useful drug. In most cases, these inaccuracies arise from the candidate drugs sticking together during the screen to create particles that physically, instead of chemically, block the activity of the molecule targeted by the drug. Such inaccuracies are only now discovered in the slower and more expensive second stage of screening, resulting in significant time and money wasted during the drug discovery process.
Hoare and Mateen have come up with a way to improve the first stage of testing by using a new printable hydrogel, a network of polymers used in everything from contact lenses to disposable diapers. The thin layers of printed hydrogels can form a cage around the target molecule so drug particles formed can’t access the target molecule and trigger the inaccurate result. Instead, only drugs that chemically bind to the target molecule (the ones that could become practical drugs) are allowed into the hydrogel to give a positive result. The printed device developed is inexpensive and can be used directly in drug screening, improving accuracy without requiring a significant change in how drug screening is now done. As an added benefit, the same sensitivity can be achieved using much less sample volume, further reducing the cost of the screen.
“We had already developed the printing method, but were not sure what to do with the materials,” Mateen said. “Reading about this significant issue in the area of drug screening made me realize that these materials could directly address this problem in a simple and effective way.”
The researchers expect this to make testing more affordable and to speed up the discovery of new drugs. In addition, to help address the surge of antibiotic resistance, the technology can also help to more quickly identify “helper drugs” that can make even drug-resistant bacteria susceptible to our current antibiotics.
“As the next step, we are looking for industry partners to prove the effectiveness of our technology on a full-scale screen of thousands of molecules that can help to extend the lifetime of our current antibiotics,” Hoare said. “We are optimistic this approach can help to bring new effective drugs to patients faster than is currently possible”.
The Latest on: Drug discovery
- Horizon Discovery inks exclusive pact with C4XD to deliver potential new cancer drugs on December 16, 2018 at 11:40 pm
StockMarketWire.com - Horizon Discovery Group on Monday inked an exclusive partnership ... to discover pre-clinical drug candidates using novel synthetic lethal oncology targets that Horizon had ident... […]
- Baculovirus Paves the Way for New Drug Discovery on December 16, 2018 at 10:30 pm
Baculovirus virion(BV) induced innate immunity completely eliminates the liver stage dormant hypnozoites of Plasmodium vivax in a mouse model. This can lead to the discovery of new and more effective ... […]
- Cancer Immunotherapy Drug Discovery Outsourcing Market is grow with 14.0% CAGR during the forecast time period 2018-2026 on December 14, 2018 at 3:21 am
The global cancer immunotherapy drug discovery outsourcing market size is anticipated to around USD 1.8 billion by 2026, this market is anticipated to grow with 14.0% CAGR during the forecast time per... […]
- CETSA HT in early drug discovery through screening against B-Raf and PARP1 on December 13, 2018 at 5:04 pm
We allow third-party companies to serve ads and/or collect anonymous information. These companies may use non-personally identifiable information (browser type, time and date) in order to provide adve... […]
- Drug Discovery Informatics Market - Technology, Trends, Development, Key Manufacturers Analysis and Forecast to 2025 on December 13, 2018 at 12:44 pm
Some of the key players influencing the market are PerkinElmer, Inc., Schrödinger, LLC, Certara, L.P., Infosys Limited, IBM, Collaborative Drug Discovery, Inc., Jubilant Life Sciences Ltd ... […]
- X-Chem, Almirall forge dermatology-focused drug discovery alliance on December 13, 2018 at 3:08 am
Under the terms of the agreement, X-Chem will utilize its industry-leading DNA-encoded library (DEX) screening platform and proprietary informatics tools to search for novel hits for Almirall targets. ... […]
- Killing the liver-stage malaria parasite with baculovirus: a drug discovery approach on December 12, 2018 at 7:45 am
A proportion of P. vivax sporozoites differentiate to a hypnozoite form that ultimately reactivates and proliferates leading to a blood-stage relapse. The hypnozoites are not eradicated by ... […]
- Almirall and X-Chem Announce Dermatology-Focused Drug Discovery Collaboration on December 12, 2018 at 4:15 am
X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, announced today a drug discovery p... […]
- Schrödinger, TB Alliance collaborate to advance tuberculosis drug discovery on December 12, 2018 at 3:45 am
Schrödinger and TB Alliance have entered into a three-year research collaboration to enhance the development of next-generation tuberculosis (TB) treatments by leveraging Schrödinger’s advanced comput... […]
- Insilico Medicine to showcase its AI Engine for Future Drug Discovery at the 2018 Future Tech Forum on December 10, 2018 at 9:52 am
IMAGE: Artur Kadurin, Chief AI Officer and CEO of Insilico Taiwan presents "AI in Drug Discovery Creates the Best Era of Precision Medicine " at the 2018 Future Tech Forum. view more Monday, December ... […]
via Google News and Bing News